BPC-157 + TB-500 + KPV + Larazotide (Capsule)

BPC-157 + TB-500 + KPV + Larazotide Oral Capsule

A comprehensive gut healing formula combining four complementary peptides for leaky gut, IBD, and intestinal repair.

100% 50% · t½ Time → Serum level
Molecular Weight Not specified
Half-Life Varies
Typical Dose One capsule (per prescriber guidance)
Cycle Length 8–12 weeks

Description

This advanced oral capsule represents one of the most comprehensive gut healing formulas available, combining four peptides with distinct and complementary mechanisms targeting every major aspect of intestinal dysfunction. BPC-157 provides foundational mucosal repair and angiogenesis; TB-500 contributes systemic anti-inflammatory and healing effects; KPV (Lys-Pro-Val, a tripeptide derived from alpha-MSH) delivers potent localized anti-inflammatory action in the gut; and Larazotide acetate (AT-1001) directly stabilizes tight junction proteins to reduce intestinal permeability. Larazotide has been the subject of multiple human clinical trials for celiac disease and has demonstrated statistically significant reductions in intestinal permeability markers. This combination is particularly relevant for conditions including leaky gut syndrome, celiac disease, Crohn’s disease, ulcerative colitis, and general intestinal hyperpermeability associated with chronic inflammation or autoimmune conditions.

Key Characteristics

Molecular Formula

Molecular Weight

Half-Life

Administration Routes

Oral capsule

Typical Dose

One capsule (per prescriber guidance)

Frequency

Daily

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“A comprehensive gut healing formula combining four complementary peptides for leaky gut, IBD, and intestinal repair.”

BPC-157 activates the FAK-paxillin signaling pathway to promote epithelial cell migration and mucosal repair, while stimulating VEGF-mediated angiogenesis to restore blood supply to damaged intestinal tissue. TB-500 regulates actin dynamics through G-actin sequestration, facilitating cell migration necessary for wound closure and tissue reconstruction. KPV acts as a potent inhibitor of NF-κB nuclear translocation, reducing transcription of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in intestinal epithelial cells and macrophages. Larazotide (AT-1001) is a 8-amino acid peptide that acts as a tight junction regulator — it competitively inhibits zonulin (a tight junction modulator) and stabilizes occludin and claudin-1 proteins that form the physical barrier between intestinal cells. The combined action of these four peptides addresses mucosal repair, inflammation, cell migration, and barrier function simultaneously, providing a comprehensive approach to intestinal healing.

Administration Routes

Oral capsule

Key Characteristics

Typical Dose

One capsule (per prescriber guidance)

Frequency

Daily

Cycle Length

8–12 weeks

Administration

Oral capsule

Protocol Notes

Take on empty stomach for best GI absorption. Particularly valuable for leaky gut syndrome, celiac disease, IBD, and intestinal permeability issues.

Reconstitution Guide

Storage Information

Store at room temperature, away from light and moisture.

Quality & Sourcing Standards

When sourcing BPC-157 + TB-500 + KPV + Larazotide (Capsule) for research purposes, the following quality benchmarks should be verified before use.

Purity:

>98% (verified by HPLC)

Certificate of Analysis (COA):

Must be provided by supplier

Endotoxin Testing:

<0.1 EU/mg (prevents bacterial contamination)

GMP Compliance:

Manufactured in cGMP-certified facility

Third-Party Testing:

Independent lab verification preferred

Storage Information

Store at room temperature, away from light and moisture.

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.

Research Highlights

1

Larazotide Phase II trials for celiac disease showed reduced intestinal permeability

2

KPV demonstrated potent anti-inflammatory effects in IBD models

3

BPC-157 GI protective effects validated in 100+ preclinical studies

Evidence Level

Primarily animal studies with limited human data. Mechanism is plausible but clinical efficacy is unconfirmed.

Compatible Peptides

Peptides commonly used alongside BPC-157 + TB-500 + KPV + Larazotide (Capsule) for synergistic effects.

Thymosin α1

The most clinically validated immunomodulatory peptide, approved in 35+ countries for hepatitis, sepsis, and immune deficiency.

BPC-157 (Capsule)

Oral BPC-157 for gastrointestinal healing, gut permeability, and systemic anti-inflammatory effects.

Quick Reference

Category

Blends & Combos

Status

Research Only

Dose

One capsule (per prescriber guidance)

Frequency

Daily

Cycle

8–12 weeks